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EDITORIAL REVIEW
Acquired resistance to acute renal failure
For the past forty years and more, acute renal failure (ARF)
has been a focus of attention in clinical medicine. Despite
numerous clinical and experimental studies, however, the de-
tailed mechanisms responsible for ARF have not been well
established. Furthermore, a number of treatments or proce-
dures were examined to prevent the development of ARF
and/or to accelerate recovery from renal failure, but their
efficacy has not been proved conclusively.
On the other hand, recurrence of ARF seems to be an unusual
clinical phenomenon. The mechanisms for acquired resistance
to ARF are poorly understood, but suggested mechanisms
include the prevention of tubular obstruction and back—leakage
of filtrate through increased resistance of regenerated tubular
epithelium to ARF challenge and/or through solute diuresis.
Furthermore, recent evidence suggests the prevention of a
reduction in glomerular filtration through a loss of glomerular
responses to contractile stimuli, involving angiotensin.
This review is focused on acquired resistance to ARF in the
hope that it might contribute to the understanding of the
pathogenesis and prevention of ARF.
Animal models of ARF
Various kinds of animal models have been used for exploring
the pathogenesis of ARF. These models of renal failure could be
classified into ischemic, nephrotoxic and myohemoglobinuric
ARF. To produce ischemic renal failure, two principal proce-
dures have been widely used: 1) a mechanical clamping of the
renal artery, and 2) an intrarenal infusion of norepinephrine.
Experimental nephrotoxic ARF is induced by the intravenous
or intramuscular injection of nephrotoxic substances such as
uranyl nitrate, mercuric chloride, potassium dichromate, ami-
noglycoside and cisplatin. Animal models of myohemoglobin-
uric ARF have been produced via the intravenous injection of
methemoglobin along with additional procedures such as dehy-
dration and/or metabolic acidosis, or by the intramuscular or
subcutaneous injection of hypertonic glycerol solution.
Although these forms of ARF are not completely comparable
to those in humans, vigorous investigations on these models
have advanced our knowledge of ARF. Controversy still exists,
however, concerning the detailed mechanisms involved in the
pathogenesis of ARF. Suggested mechanisms for producing and
maintaining renal failure include: 1) a primary reduction of
glomerular filtration due to cortical and glomerular hemody-
namic changes or to reduced glomerular permeability; 2) tubu-
lar obstruction by casts and cellular debris; and 3) back—leakage
of filtrate across damaged tubular epithelia. Accumulating evi-
dence indicates that the role of these pathogenic factors may
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differ with different models and at different stages of renal
failure [1—4], as summarized in Table 1.
Resistance to ARF
It is well known that animals recovering from prior ARF are
resistant to a subsequent renal failure challenge with the same
agent [5—10], though it is not an universal finding [11—13] (Table
2). Animals recovering from uranium— or glycerol—induced
ARF were protected against a rechallenge with the agents [5—9].
Also, insensitivity to the nephrotoxic effects of gentamicin
developed during a daily administration [10]. In contrast with
these non-ischemic models, resistance to ARF has not been
clearly demonstrated in the ischemic model [11—13].
Also, accumulating data suggest cross—protection between
different models of renal failure [14—17], but it is not a common
feature of all models [13, 16—19] (Table 3). Prior glycerol
induced ARF protected rats against mercuric chloride—medi-
ated nephropathy, and mercury poisoning afforded insensitivity
to the nephrotoxicity of glycerol [14]. Pretreatment with potas-
sium dichromate, which produced tubular necrosis in the same
part of the renal cortex as gentamicin, ameliorated gentamicin
mediated ARF, but did not modify gentamicin—mediated tubu-
lar dysfunction and morphologic damage [16]. On the contrary,
prior administration of netilmicin, a nontoxic aminoglycoside
which did not produce necrosis, was found to increase the
kidney's susceptibility to gentamicin [16]. Recovery of the
creatinine clearance rate in mercury poisoned rats was not
delayed by the concomitant administration of gentamicin in
doses sufficient to produce pronounced azotemia [17]. When
the sequence of mercuric chloride and gentamicin was re-
versed, however, mercuric chloride—induced ARF was more
severe in gentamicin treated rats than in non-treated animals, a
finding which indicates increased susceptibility to mercuric
chloride.
There is no evidence that cross—resistance develops between
ischemic and other models of renal failure (Table 3). Rather
gentamicin increases the susceptibility of the kidney to acute
ischemic injury [18], as described later. Cross—resistance did
not develop between ischemic and myohemoglobinuric ARF in
rats [19]. Rabbits recovering from uranyl acetate—induced ARF
were not protected against an acute ischemic injury, while prior
ischemic ARF afforded a partial resistance to the nephrotoxic-
ity of uranium [13].
The degree of acquired resistance to ARF may differ with
different models of renal failure. In the uranium model, it was
related to severity of prior ARF [6]. Animals recovering from
uranium—induced ARF were resistant to a rechallenge with a
larger dose of the agent [6]. On the other hand, a study [14] on
cross—protection between glycerol- and mercuric chloride—in-
duced ARF in rats showed that the degree of the protection
conferred by prior ARF does not depend on the severity of
renal functional impairment induced. In the glycerol model,
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Table 1. Pathogenetic factors operative in experimental ARF
Model
Decreased
RBF
Decreased
K
Tubular
obstruction
Filtrate
leak
Ischemic + ? ++ +, ++
Uranium — ++ ? ++
Mercuric chloride — ? + ++
Gentamicin + ++ ? —
Glycerol -H- ? + —
Abbreviations are: ARF, acute renal failure; RBF, renal blood flow;
K, glomerular ultrafiltration coefficient; +, mechanism is operative; —,
mechanism is not always operative; ?, mechanism is not evaluated
adequately.
resistance to a rechallenge with the same agent has been
demonstrated 35 days after the initial administration [7]. No
evidence of residual resistance to the gentamicin nephrotoxicity
was obtained six months after recovery from gentamicin—in-
duced ARF [10]. In this study, doubling the dose of gentamicin
during the recovery phase overwhelmed insensitivity to the
agent, and caused a second episode of ARF.
In summary, nephrotoxic or myohemoglobinuric ARF pro-
tects renal function against a subsequent nephrotoxic injury. In
contrast, resistance to ARF does not develop clearly in the
ischemic model. More clinically important, pretreatment with
gentamicin increases the kidney's susceptibility to ischemic and
nephrotoxic insults, Acquired resistance to ARF seems to be an
incomplete and transient phenomenon.
Mechanisms for acquired resistance to ARF
Hemodynamic factors
Accumulating evidence indicates that the pathogenetic role of
renal hemodynamic alterations may differ with different models
and at different stages of renal failure [1—4] (Table 1). Renal
ischemia is not always necessary for the development and
maintenance of nephrotoxic ARF. On the contrary, renal vaso-
constriction plays a fundamental role in an initial reduction in
GFR in the glycerol model. Mediators of renal hemodynamic
alterations in ARF have not been well established [2, 4]. Of
suggested mediators, the renin—angiotensin system has at-
tracted much attention. Since the first documentation by
Goormaghtigh [20], numerous studies have been performed to
explore the possibility of a causative role of the renin—angi-
otensin system in ARF. Controversy still exists, however,
regarding the role of this system [1, 21].
On the other hand, there is a paucity of data concerning renal
hemodynamic alterations following a second ARF insult. In the
uranium model, any significant difference was not found in
changes of renal blood flow or the intracortical flow distribution
following a second renal failure challenge between ARF-resis-
tant and -nonresistant animals [6, 131, indicating no correlation
between renal hemodynamics and resistance to ARF.
Also, there is no evidence to support a possibility that
suppressed renin—angiotensin activity plays a fundamental role
in the development of renal resistance to ARF. Oken et al [14]
and Carvalho, Landwehr and Oken [22] have demonstrated that
renin store in the kidneys and the plasma level of renin
substrate are entirely normal or supernormal in rats recovering
from glycerol- or mercuric chloride—induced ARF. In these
animals, hemorrhage produced changes in blood pressure and
plasma renin titer equivalent to those in normal animals [22].
Therefore, refractoriness to a second bout of ARF in animals
recovering from prior renal failure cannot be attributed to
impaired renin release or inadequate plasma renin substrate.
Intraglomerular factors
A recent study [23] has pointed to intraglomerular events as
a major determinant of the glomerular filtration rate (GFR).
Micropuncture studies [24, 25] have demonstrated that the
glomerular ultrafiltration coefficient (hydraulic conductivity
multiplied by filtration surface area) decreases in the uranium
and gentamicin models (Table 1), indicating changes in hydrau-
lic conductivity and/or filtration area. Morphologic observa-
tions with scanning electron microscopy disclosed changes in
the glomerular ultrastructure in ARF animals, characterized by
a loss of foot processes associated with a narrowing of
interpedicular spaces, and/or by a reduction in the diameter and
density of endothelial fenestrae [26—30]. A number of investi-
gations demonstrated an elevation in the plasma renin activity,
angiotensin II [21, 31—33] and vasopressin [34], and increased
sympathetic nerve activity [35] during the initiation and main-
tenance stages of ARF.
On the other hand, exogenous angiotensin I and II produced
glomerular ultrastructural changes similar to those in ARF [36,
37]. Both angiotensin II and arginine vasopressin were found to
produce a significant decline in the glomerular ultrafiltration
coefficient and filtration rate [38—40]. Also, these vasoconstric-
tor substances are known to stimulate mesangial cell contrac-
tion in vitro [41, 42]. Specific angiotensin II receptors are
thought to reside in the glomerular mesangial cells [43, 44].
Furthermore, bundles of fine myofilaments similar to those of
smooth muscle are found in nonphagocytic mesangial cells [45,
46]. From these observations, Schor, Ichikawa and Brenner
[39] have proposed the view that angiotensin II and vasopressin
are both potentially important regulators of mesangial cell
contraction, and thereby the glomerular filtration area and
ultrafiltration coefficient. If it is correct, an inhibition of mesan-
gial cell contraction should prevent a reduction in the glomer-
ular filtration area and ultrafiltration coefficient by angiotensin
or vasopressin.
Wilkes et al [15] have demonstrated that the glomerular
contractile response to angiotensin II is totally inhibited in rats
recovering from glycerol induced ARF, but the response to
dibutyryl cyclic AMP is well sustained. They suggested that the
loss of the glomerular response to angiotensin contributes, in
part, to resistance to a subsequent renal failure challenge in this
model. Apparently, the data lend argument to the view that the
loss of mesangial contractile response to angiotensin contrib-
utes to the protection of GFR against a subsequent renal failure
challenge through a well—maintained filtration area. Unfortu-
nately, no one has yet measured the ultrafiltration coefficient
following a second ARF challenge. Furthermore, Wilkes and
Bellucci [47] have noted that glomerular angiotensin II
receptor—binding does not alter during the course of ischemic or
mercuric chloride—induced ARF, and suggested the possibility
of a defect at the postreceptor level in ARF.
In our study, an angiotensin converting enzyme inhibitor
(captopril) did not prevent uranium induced ARF nor glomeru-
lar ultrastructural changes [37]. Also, rabbits recovering from
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Table 2. Resistance to a rechallenge with the same agent
Agent Animal
Protection
ReferencesFunctional Morphological
UN_UNa
UA_UAb
Glycerol—glycerol
GM__GMC
Ischemia—ischemia
dog
rabbit
rat
rat
rat, rabbit
rat
rat
rabbit
present
present
present
present (tubular function)
not examined
present
variable
absent
present
present
not examined
not examined
present
present
variable
absent
[5]
[6]
[7]
[8]
[9]
[10]
[11, 12]
[13]
a UN, uranyl nitrate
b UA, uranyl acetate
GM, gentamicin
Table 3. Cross—protection between different ARF
Agent Animal
Protection
ReferencesFunctional Morphological
Glycerol —a HgCl2
HgCI2 —a glycerol
PD — GM
Netilmicin —a GM
HgCI2 —a GM
GM —a HgCI2
UA —a ischemia
Ischemia —a UA
GM —a ischemia
Ischemia —a glycerol
Glycerol —a ischemia
rat
rat
rat
rat
rat
rat
rabbit
rabbit
rat
rat
rat
present
present
present
exacerbate
present
exacerbate
absent
partial
exacerbate
absent
absent
not examined
not examined
absent
—
absent
—
absent
partial
exacerbate
not examined
not examined
[14]
[14]
[16]
[16]
[17]
[17]
[13]
[13]
[18]
[19]
[19]
a PD, potassium dichromate; other abbreviations are in Table 2.
uranium induced ARF showed a complete inhibition of the
glomerular contractile response not only to angiotensin but also
to vasopressin or norepinephrine (Note added in proof). More
interestingly, animals recovering from ischemic ARF were not
resistant to an additional ischemia, despite inhibited glomerular
response to angiotensin II (Note added in proof). It is unlikely,
therefore, that resistance to ARF is largely attributed to sup-
pressed glomerular contractile response to angiotensin in these
models.
Furthermore, controversy exists concerning a reduction in
the glomerular capillary surface area by mesangial cell contrac-
tion [48—50]. Haley et at [48] noted that angiotensin II reduces
the mesangium area but does not alter the capillary surface
area. Zimmerhackl et al [50] demontrated that alterations of the
glomerular ultrafiltration coefficient are not induced by uniform
capillary vasoconstriction mechanisms. In the uranium model,
glomerular ultrastructural changes occurred after a second
renal failure challenge in ARF-resistant rabbits, despite a loss of
glomerular responses to contractile stimuli [51]. These data also
argue against the view that suppressed glomerular contractility
protects glomerular filtration against a subsequent renal—failure
challenge in ARF animals via well—maintained glomerular cap-
illary surface—area. What is more interesting is that angiotensin
II reduces blood flow more in the long pathways of the
glomerular capillary network than in the short pathways [SO], a
finding which suggests that angiotensin II reduces the effective
glomerular filtration area through intraglomerular blood—flow
redistribution. It is unclear, however, whether or not mesangial
cell contraction regulates the intraglomerular flow distribution.
Tubular factors
Renal tubular damage predisposes to the back—leakage of
filtrate in the ischemic, uranium and mercuric chloride models
of ARF, and thereby contributes to a decline in whole kidney
GFR [52, 53] (Table 1). In contrast, the passive backleak
accounts for only small portion of a reduction in GFR in
methemoglobinuric ARF [53]. Tubular obstruction due to cell-
ular debris and casts is demonstrable during the initiation and
maintenance phases of the ischemic, mercuric chloride and
glycerol models [1, 3, 4, 54]. This obstruction also results in a
reduction in GFR.
On the other hand, numerous studies have demonstrated high
resistance of regenerated tubular cells to a subsequent renal
failure challenge in nephrotoxic ARF, but not in the ischemic
model. In 1912, Suzuki noted in his study on the localization of
the nephrotoxic action of uranium that regenerated tubular cells
are resistant to a rechallenge with the same agent. Thereafter,
his finding was confirmed by several investigators. MacNider
[5] has found in uranium poisoned dogs that repair of the
degenerated tubular epithelium is accomplished through the
following two processes: 1) a regeneration of proximal convo-
luted tubules from the cells not too severely damaged; and 2) a
regeneration that occurs as an ingrowth of cells or as syncytial
buds from epithelial cells in the terminal portion of the proximal
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convoluted tubules or from the upper end of the descending
limb of Henle's loop. The latter type of regenerated epithelial
cells was resistant to a rechallenge with a larger dose of
uranium, but the former type was not. Associated with this
morphological resistance, renal functional resistance also de-
veloped. The degree of the decline in phenolsulfonphthalein
excretion and creatinine clearance and the retention of urea
nitrogen and creatinine was significantly less on the rechallenge
than on the initial administration. The previous study from our
laboratory [6] demonstrated that severity of tubular necrosis
and intratubular cast formation following a rechallenge with a
larger dose of uranium is significantly lessened in previously
uranium—treated rabbits when compared to animals subjected
to a single injection, concomitant with a less reduction in whole
kidney GFR.
The renal epithelium eventually becomes refractory to the
effects of glycerol during repeated injections [9]. Hayes et al [7]
noticed in the glycerol model that the retention of urea nitrogen
and the decline in urine osmolality following a rechallenge with
glycerol are significantly ameliorated when compared to those
seen after the first administration. Westenfelder et al [8] also
demonstrated in rats that glycerol induced ARF affords tubular
functional protection against a rechallenge with the same agent.
In this study, animals recovering from myohemoglobinuric
ARF showed normal proximal tubular—reabsorption of glucose
and bicarbonate, and normal distal tubular—acidification even
after the rechallenge. However, whole kidney GFR fell follow-
ing the rechallenge, a finding which suggests a minor contribu-
tion of tubular factors to the decline in GFR in this ARF model.
Elliott et al [10] have demonstrated that the nephrotoxicity of
gentamicin is significantly alleviated during continued adminis-
tration, and functional and structural recovery occurs thereaf-
ter. The rate and ultimate degree of recovery of the kidney
structure, inulin clearance rate and renal cortical uptake of
para-aminohippurate in vitro were not reduced by continued
administration. In the gentamicin model, a reduction in the
glomerular ultrafiltration coefficient seems to be a major
pathophysiologic event [25] (Table 1). Back—leakage of filtrate
and tubular obstruction do not play important roles in a decline
in whole kidney GFR [3]. Therefore, the recovery of GFR
despite continued gentamicin administration might be due to
modification of the glomerular permeability rather than to
resistance of regenerated tubular cells to ARF insults. No
information is available, however, regarding the ultrafiltration
coefficient in the recovery phase of gentamicin induced ARF.
A question arises as to why regenerated tubular cells are
resistant to a second injury. One possibility would be that the
resistance is due to a failure of the damaged kidney to concen-
trate the toxic substance. Our preliminary study demonstrated,
however, that the kidney with prior uranium—induced ARF
achieves similar renal tissue levels of uranium as the previously
unchallenged kidney when subjected to the second injection
(unpublished data). A likely alternative is that regenerated renal
tubules may be resistant to the influx of calcium, which is a
necessary prerequisite for cell death. To ascertain it, more
biochemical work needs to be done.
One of the other tubular factors possibly responsible for
resistance to ARF is solute diuresis caused by prior renal
failure. There is a possibility that solute diuresis prevents ARF
through an elevation of intratubular pressure and prevention of
tubular obstruction. Some investigators [55—57] suggested that
the prevention of ARF by chronic saline loading, vasodilators
or diuretics is due to enhanced urinary solute excretion rather
than to suppressed renin—angiotensin activity or increased renal
blood—flow.
On the other hand, scant evidence is available to support a
causative role of solute diuresis in the kidney's insensitivity to
a subsequent renal failure challenge. Zager et al [11] noted in
ischemic ARF rats that the intraperitoneal injection of normal
urine or solute—matched artificial urine produces solute diuresis
and protects against additional ischemic events, and suggested
that this protection is possibly due to ARF induced increments
in solute loads per nephron. On the contrary, increased solute
excretion per nephron, caused by partial nephrectomy, could
not protect rats from glycerol induced ARF [7]. Also, increased
solute diuresis per functioning nephron did not occur during the
recovery phase of glycerol induced ARF, but resistance to ARF
developed [14, 58].
In summary, acquired resistance to ARF cannot be attributed
to modified renal hemodynamics nor to impaired renin—angi-
otensin system. It is unlikely that inhibited glomerular re-
sponses to contractile stimuli contribute largely to renal
refractoriness to a subsequent renal failure challenge. There is
a possibility that this renal refractoriness is due to entirely
different mechanisms. One possibility would be the resistance
of regenerated tubular cells to the influx of calcium. A contri-
bution of ARF-induced solute diuresis to resistance to a second
renal failure challenge seems to be small.
Increased susceptibility to ARF
Sublethal renal tubular injury may increase the susceptibility
of the kidney to a second renal injury [5, 12]. In the ischemic
model, the kidney with severe ischemic injury showed in-
creased resistance to an additional ischemia if rechallenged at
or near the height of functional and morphologic damage,
whereas prior mild ischemic injury transiently reduced resist-
ance to a subsequent ischemic insult [11, 12].
During continued gentamicin administration, renal tubular
cells not yet undergoing active regeneration seems to be unusu-
ally susceptible to ischemia [18]. Zager and Sharma [18] de-
scribed that renal ischemia produces far more intratubular
cellular debris in gentamicin treated rats than in non-treated
animals. Proximal tubular injury due to gentamicin antedates
overt gentamicin nephrotoxicity [59, 60]. This tubular damage
may render proximal tubular cells more susceptible to ischemic
tubular necrosis, and thereby exacerbate both tubular obstruc-
tion and back—leakage of filtrate, which are major pathophysi-
ologic events in ischemic ARF [1—3]. Furthermore, gentamicin
produces a decline in the glomerular ultrafiltration coefficient
[25]. It is possible, therefore, that gentamicin exacerbates
ischemic ARF by acting at both glomerular and tubular levels.
Also, gentamicin appears to enhance the nephrotoxicity of
mercuric chloride [17]. Gentamicin and mercuric chloride are
both nephrotoxic but affect different parts of the renal tubules.
Toxicity of mercuric chloride is most manifest in the pars recta
[61], while gentamicin affects primarily the proximal convoluted
tubules [59, 60]. The pretreatment with gentamicin induces a
reduction in GFR and an increase in urine output [3, 17]. This
gentamicin mediated polyuria probably results in dehydration,
which predisposes to ARF. Furthermore, the renal tubular
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